GHK-Cu
โ ๏ธ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Copper-binding tripeptide; epigenetic modulator of 4,000+ genes driving tissue remodeling, collagen synthesis, and antioxidant defense
Quick Facts
| Property | Value |
|---|---|
| Also Known As | Glycyl-L-Histidyl-L-Lysine Copper Complex, Copper Tripeptide-1, Prezatide Copper |
| Category | Anti-Aging / Cosmetic / Recovery |
| Sequence | GHK (Gly-His-Lys) + Cuยฒโบ |
| Molecular Weight | ~405 Da (copper complex) |
| Molecular Formula | CโโHโโNโ OโยทCu |
| PubChem CID | 73587 |
| Administration | Topical / SubQ / With Microneedling |
| Typical Dose Range | Topical: 0.05โ2% cream/serum; Injectable: 1โ2 mg/day SubQ |
| Half-Life | Not well characterized; copper complex is metabolized systemically |
| Storage | Lyophilized: -20ยฐC, 2โ3 years (desiccated, light-protected); Reconstituted: 2โ8ยฐC, 3โ4 weeks. Degradation: blue/violet โ green/yellow = discard |
| FDA Status | Topical: cosmetic ingredient (Category 1); Injectable: Research-only (Category 2) |
| WADA Status | Prohibited under S0 (Non-Approved Substances) |
Mechanism of Action
GHK-Cu is a naturally occurring copper-binding tripeptide first isolated from human plasma by Pickart in 1973. Its primary mechanism is broad genomic modulation โ GHK resets the expression of over 4,000 human genes (approximately 6% of the genome), upregulating 59% (repair, antioxidant defense, stem cell maintenance) and downregulating 41% (inflammation, metastasis, tissue destruction). This was demonstrated using the Broad Institute Connectivity Map at 1 ฮผM concentration (PMID-25302294).
At the tissue level, GHK-Cu drives ECM remodeling through a dual mechanism: simultaneously increasing collagen I/III synthesis (up to 70%), elastin, and glycosaminoglycans while upregulating MMP-2 with compensatory TIMP-1/2 increases โ creating "smart remodeling" that builds new matrix while clearing damaged tissue. It acts as a chemoattractant for macrophages, mast cells, and capillary endothelial cells, and stimulates fibroblast and keratinocyte proliferation for wound repair (PMID-18644225).
GHK-Cu also provides potent antioxidant defense by delivering copper to Cu,Zn-SOD and blocking iron release from ferritin (87% reduction). It inhibits NF-ฮบB and p38 MAPK, reducing TNF-ฮฑ and IL-6. The gene expression modulation extends to neurological function โ GHK resets pathological gene expression patterns associated with Alzheimer's and Parkinson's diseases toward healthier states (PMID-28212278).
A high-impact 2023 study demonstrated that plasma GHK levels are significantly decreased in COPD patients, and GHK-Cu treatment rescues smoking-induced skeletal muscle dysfunction via SIRT1 activation โ linking GHK-Cu to sirtuin/longevity biology (PMID-36905132).
Key Research Areas
-
Gene Expression Modulation (4,000+ genes) โ Pickart's landmark work using the Connectivity Map showed GHK resets diseased cell gene expression (cancer, COPD) toward healthier states, modulating genes involved in DNA repair, antioxidant defense, and inflammation suppression (PMID-25302294, PMID-26236730).
-
Skin Aging and Wound Healing โ GHK-Cu increases collagen, elastin, and GAG synthesis. Clinical skin studies show tightening, wrinkle reduction, and improved clarity. GHK-Cu liposomes enhanced scald wound healing by 33% with accelerated angiogenesis (PMID-18644225, PMID-28370978).
-
Neuroprotection and Cognitive Decline โ Gene expression analysis reveals GHK modulates patterns relevant to Alzheimer's, Parkinson's, and age-related cognitive decline through antioxidant and anti-inflammatory pathways (PMID-28212278).
-
COPD and Sarcopenia โ Plasma GHK decreased in COPD patients; GHK-Cu treatment rescued smoking-induced muscle dysfunction via SIRT1 pathway (J Cachexia Sarcopenia Muscle, IF ~9.4) (PMID-36905132).
-
Pulmonary Anti-Inflammation โ GHK-Cu reduced ROS, increased SOD, and decreased TNF-ฮฑ/IL-6 in acute lung injury models (PMID-27517151).
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human biomarker data | 1 | COPD plasma GHK levels (PMID-36905132) |
| Animal in vivo | 3 | Wound healing, lung injury, muscle dysfunction |
| In vitro / computational | 2 | Gene expression analysis (Connectivity Map) |
| Narrative reviews | 5 | Anti-aging, skin, tissue remodeling, neuroprotection |
| Total vault studies | 11 |
The evidence base for GHK-Cu is moderate with unique genomic depth. The 4,000+ gene modulation data is unparalleled among peptides, though it relies on computational analysis rather than traditional wet-lab experiments. Human data is limited to cosmetic skin studies and one COPD biomarker study. Methodological concern: Pickart (GHK discoverer and patent holder) is first author on 4 of 11 studies โ single-group concern with commercial conflict of interest.
Clinical Applications
- Anti-Aging โ Epigenetic reset, collagen synthesis, antioxidant defense
- Skin Health โ Wrinkle reduction, skin tightening, collagen/elastin synthesis
- Wound Healing โ ECM remodeling, chemoattraction, angiogenesis
- Hair Growth โ Follicle stem cell support, dermal papilla stimulation
- Post-Procedure Recovery โ Post-laser, post-peel, post-microneedling recovery
- Injury Recovery โ Tissue remodeling and anti-inflammatory effects
- Neuroprotection โ Gene expression patterns relevant to neurodegeneration
- Sarcopenia โ SIRT1-mediated muscle protection (COPD model)
Protocols Using This Peptide
- Skin Rejuvenation Protocol โ Core peptide for dermatological applications
- Anti-Aging Daily Protocol โ Daily anti-aging stack component
- Longevity Stack Protocol โ Longevity/regenerative component
- Recovery Stack Protocol โ Tissue remodeling support
- Wolverine Stack Protocol โ Present in GLOW/KLOW blend variants
Ageless Peps Products
- AP-GHKCu-Vial โ GHK-Cu Vial, $112 retail
- AP-GHKCu-2MG-Capsules โ GHK-Cu Capsules, 2mg x 60 caps, $136 retail
- AP-GLOW-Blend โ GLOW Blend (GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg), from $134 retail
- AP-KLOW-Blend โ KLOW Blend (GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg), $153 retail
Dosing Reference
Research Dosing Ranges
| Route | Dose Range | Frequency | Duration | Source | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Topical | 0.05โ2% cream/serum | 1โ2x daily | Ongoing | PMID-25302294). The evidence is conflicting โ the pro-angiogenic mechanism drives a contraindication, but the gene expression data suggests potential anti-cancer effects. Action: Avoid in active cancer until this conflict is resolved by further research.
Synergistic Combinations
Related Research
Related#peptide #anti-aging #cosmetic #recovery #subq #topical |